Zai Lab price target lowered to $37 from $55 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on Zai Lab (ZLAB) to $37 from $55 and keeps an Overweight rating on the shares. Zai Lab reported Q4 and full-year revenues of $127.6M and $460.2M, respectively, in line with consensus, though Vyvgart sales were slightly weaker than expected, the analyst tells investors in a research note. Management indicated that 2026 top-line growth is likely to be modest, with volume gains offset by pricing pressures and competition in China, the firm says.